Non-Invasive Prenatal Testing Market Size, Share & Trends Analysis Report, By Gestation Period (0-12 Weeks, 13-24 Weeks, 25-36 Weeks), By Pregnancy Risk (High & Average Risk, Low Risk), By Method (Ultrasound Detection, Biochemical Screening Tests, Cell-Free DNA in Maternal Plasma Tests), By Technology, By Product, By Application, By End-User, By Region, Forecasts, 2024-2031
The Non-Invasive Prenatal Testing Market Size is valued at USD 4.63 billion in 2023 and is predicted to reach USD 12.20 billion by the year 2031 at a 13.02 % CAGR during the forecast period for 2024-2031.
Non-invasive prenatal testing, often known as non-invasive prenatal screening, is a method for determining the likelihood that a fetus will have genetic abnormalities. This type of screening is risk-free and remarkably successful for Down syndrome, Patau syndrome, Edwards syndrome, Turner syndrome, and other genetic conditions. By week 10 of pregnancy, little DNA fragments are detected in pregnant women's blood, which is frequently examined. Reduced fertility, high blood pressure, increased risk of miscarriage, stillbirths, and maternal mortality are just a few health problems that might arise as a mother ages. Maternal age can also increase the likelihood of genetic disorders in babies due to incorrect chromosomal division.
The demand for non-invasive prenatal diagnostics is therefore anticipated to increase as maternal age and the prevalence of chromosomal disorders both rise. The market's organic revenue growth is driven by an increase in the majority of chromosomal abnormalities and increased product usage in new applications. Additionally, improvements in existing tests' chemistry, usefulness, and bioinformatics analysis are anticipated to fuel market expansion. The market for non-invasive prenatal testing is driven by older women's more significant chance of having infants with Down syndrome.
Furthermore, the rise in children with chromosomal problems and advancements in diagnostic imaging technology drives the demand for non-invasive prenatal testing. The market for non-invasive prenatal diagnostics is anticipated to benefit from expanding insurance coverage for typical and low-risk pregnancies. However, the high cost of testing and provisional diagnostic tools restricts the market's growth. Two more issues that could impede the expansion of the global non-invasive prenatal testing market are the decreased per capita healthcare spending and the inadequate test reimbursement policies.
Competitive Landscape
Some of the Major Key Players in the Non-Invasive Prenatal Testing Market are:
- Genesis Genetics (CooperSurgical, Inc.)
- Natera, Inc.
- Eurofins LifeCodexx GmbH
- Illumina, Inc. (Verinata Health, Inc.)
- Centogene N.V.
- MedGenome Labs Ltd.
- Myriad Women’s Health, Inc. (Counsyl, Inc.)
- Hoffmann-La Roche Ltd. (Ariosa Diagnostics)
- Qiagen
- Laboratory Corp. of America Holdings
- Progenity, Inc.
- Quest Diagnostics, Inc.
Market Segmentation
The non-invasive prenatal testing market is segmented by gestation period, pregnancy risk, method, technology, product, application, and end-user. Based on gestation period, the market is segmented into 0-12 weeks, 13-24 weeks, 25-36 weeks. The market is segmented by pregnancy risk into high & average risk, low risk. The market is segmented by method into ultrasound detection, biochemical screening tests, cell-free DNA in maternal plasma tests. The market is segmented by technology into NGS, array technology, and others. The market is segmented by product into consumables & reagents, instruments. The market is segmented by application into trisomy, microdeletion syndrome, and other applications. The market is segmented by end-use into hospitals & clinics, diagnostic laboratories.
The cell-free DNA in maternal plasma tests category dominated the market. Various genetic tests are increasingly used in prenatal care to forecast the likelihood of genetic abnormalities. With the advent of whole-genome sequencing, technological developments have broadened the scope of testing and made it possible to identify many more chromosomal abnormalities, including microdeletions and sex-specific ones. However, the use of ultrasound detection as a complement to the NIPT test based on cell-free DNA results in a lower market share. However, more recent technological developments and 3D-4D imaging have enhanced the test's real-time monitoring, safety, and efficacy, which is further likely to fuel the segment's expansion.
The Trisomy Category Witnessed Growth At A Rapid Rate.
The trisomy category dominated the market in 2021 because of increased chromosomal abnormalities. The prevalence of genetic illnesses is high in India. According to much research, trisomy 21 (down syndrome), which has a high incidence rate of 1 in 800 births and results in the birth of 32,000 children with down syndrome every year, is discovered in 1 in 166 newborns nationwide. Whole genome sequencing tests are now available, and they can identify a wide range of additional chromosomal abnormalities, including microdeletions and sex-specific ones.
The North American Non-Invasive Prenatal Testing Market Holds A Significant Regional Revenue Share.
The North American non-invasive prenatal testing market is expected to register the highest market share in revenue shortly. This can be attributable to several factors, including the high preterm birth rate, the developed healthcare system, and the rising maternal mortality rate. The prevalence of chromosomal abnormalities is rising, as is public awareness of the advantages of non-invasive prenatal testing. These factors are driving the market's expansion. The demand for non-invasive prenatal testing is increasing significantly due to the top firms' increased focus on diversifying their product lines, boosting the market's growth. In addition, the development of new, technologically sophisticated tests has a significant impact on the market expansion in this region. In addition, Asia Pacific is projected to grow rapidly in the global non-invasive prenatal testing market because of the expanding healthcare systems in developing nations like China and India, among others. Rising public healthcare spending and increased knowledge of non-invasive prenatal testing will be projected to boost market expansion. Additionally, non-invasive prenatal testing developments and technology improvements are anticipated to drive the market's growth during the projection period.
Non-Invasive Prenatal Testing Market Report Scope
| Report Attribute | Specifications |
| Market Size Value In 2023 | USD 4.63 Bn |
| Revenue Forecast In 2031 | USD 12.20 Bn |
| Growth Rate CAGR | CAGR of 13.02% from 2024 to 2031 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
| Historic Year | 2019 to 2023 |
| Forecast Year | 2024-2031 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Gestation Period, By Pregnancy Risk, By Method, By Technology, By Product, By Application, By End-User, and By Region |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
| Competitive Landscape | Genesis Genetics (CooperSurgical, Inc.), Natera, Inc., Eurofins LifeCodexx GmbH, Illumina, Inc. (Verinata Health, Inc.), Centogene N.V., MedGenome Labs Ltd., Myriad Women’s Health, Inc. (Counsyl, Inc.), F. Hoffmann-La Roche Ltd. (Ariosa Diagnostics), Qiagen, Laboratory Corp. of America Holdings, Progenity, Inc., Quest Diagnostics, Inc. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation of Non-Invasive Prenatal Testing Market
Non-Invasive Prenatal Testing Market- By Gestation Period
- 0-12 Weeks
- 13-24 Weeks
- 25-36 Weeks
Non-Invasive Prenatal Testing Market- By Pregnancy Risk
- High & Average Risk
- Low Risk
Non-Invasive Prenatal Testing Market- By Method
- Ultrasound Detection
- Biochemical Screening Tests
- Cell-Free DNA in Maternal Plasma Tests
Non-Invasive Prenatal Testing Market- By Technology
- NGS
- Array Technology
- PCR
- Others
Non-Invasive Prenatal Testing Market- By Product
- Consumables & Reagents
- Instruments
Non-Invasive Prenatal Testing Market- By Application
- Trisomy
- Microdeletion Syndrome
- Other Applications
Non-Invasive Prenatal Testing Market- By End-use
- Hospitals & Clinics
- Diagnostic Laboratories
By Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
The Non-Invasive Prenatal Testing Market Size is valued at USD 4.63 billion in 2023 and is predicted to reach USD 12.20 billion by the year 2031.
The Non-Invasive Prenatal Testing Market is expected to grow at a 13.02 % CAGR during the forecast period for 2024-2031.
Genesis Genetics (CooperSurgical, Inc.), Natera, Inc., Eurofins LifeCodexx GmbH, Illumina, Inc. (Verinata Health, Inc.), Centogene N.V., MedGenome Lab